The senotherapeutic drug ABT-737 disrupts aberrant p21 expression to restore liver regeneration in adult mice

Ritschka, Birgit, 1985-; Knauer-Meyer, Tania; Sampaio Gonçalves, Daniel; Mas, Alba; Plassat, Jean-Luc; Durik, Matej; Jacobs, Hugues; Pedone, Elisa, 1985-; Di Vicino, Umberto; Cosma, Maria Pia, 1970-; Keyes, William M., 1973-

doi:http://dx.doi.org/10.1101/gad.332643.119

The senotherapeutic drug ABT-737 disrupts aberrant p21 expression to restore liver regeneration in adult mice

License

Citation

Ritschka B, Knauer-Meyer T, Gonçalves DS, Mas A, Plassat JL, Durik M et al. The senotherapeutic drug ABT-737 disrupts aberrant p21 expression to restore liver regeneration in adult mice. Genes Dev. 2020 Apr 1; 34(7-8): 489-494. DOI: 10.1101/gad.332643.119

Abstract

Young mammals possess a limited regenerative capacity in some tissues, which is lost upon maturation. We investigated whether cellular senescence might play a role in such loss during liver regeneration. We found that following partial hepatectomy, the senescence-associated genes p21, p16Ink4a, and p19Arf become dynamically expressed in different cell types when regenerative capacity decreases, but without a full senescent response. However, we show that treatment with a senescence-inhibiting drug improves regeneration, by disrupting aberrantly prolonged p21 expression. This work suggests that senescence may initially develop from heterogeneous cellular responses, and that senotherapeutic drugs might be useful in promoting organ regeneration.